» Articles » PMID: 32095298

Treatment of a Woman with Inoperable Meningioma Using Mifepristone for 26 Years

Overview
Publisher Wiley
Specialty Neurology
Date 2020 Feb 26
PMID 32095298
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Meningioma treatment includes observation of its growth or surgery with or without associated radiotherapy. However, drug treatment can be used for tumors deemed inoperable because of their size and location. Due to the presence of progesterone receptors, the use of antiprogestin mifepristone is recommended. This study describes a case of inoperable meningioma treated with mifepristone for 26 years without interruption. The patient is a 45-year-old woman diagnosed with plaque meningioma, extending from the bottom of her right orbit, through the length of the small wing of the sphenoid, part of the large wing of the sphenoid, especially near the superior orbital fissure, and at the ceiling of the orbit. As this meningioma was considered inoperable, treatment with 200 mg oral mifepristone was administered uninterruptedly for 26 years. This treatment initially halted the growth of the meningioma and subsequently resulted in a small reduction of its volume; however, the meningioma has persisted until the last evaluation. After five years of mifepristone use, hydroxyurea was added for nine months but was discontinued due to anemia and leucopenia. In conclusion, mifepristone was useful for the survival of the patient for those 26 years. The drug interfered with the natural history of the meningioma, which generally evolves to death in such long follow-up durations without associated surgery or radiation therapy.

Citing Articles

Antiproliferative effect of mifepristone (RU486) on human neuroblastoma cells (SK-N-SH): in vitro and in vivo studies.

Casulari L, Dondi D, Pratesi G, Piva F, Milani M, Piccolella M Braz J Med Biol Res. 2020; 53(11):e10067.

PMID: 33053110 PMC: 7552897. DOI: 10.1590/1414-431X202010067.

References
1.
Gupta S, Bi W, Dunn I . Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018; 44(4):E3. DOI: 10.3171/2018.1.FOCUS17754. View

2.
Mazza E, Brandes A, Zanon S, Eoli M, Lombardi G, Faedi M . Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2015; 77(1):115-20. DOI: 10.1007/s00280-015-2927-0. View

3.
Oya S, Kim S, Sade B, Lee J . The natural history of intracranial meningiomas. J Neurosurg. 2011; 114(5):1250-6. DOI: 10.3171/2010.12.JNS101623. View

4.
Claus E, Calvocoressi L, Bondy M, Schildkraut J, Wiemels J, Wrensch M . Family and personal medical history and risk of meningioma. J Neurosurg. 2011; 115(6):1072-7. PMC: 3241000. DOI: 10.3171/2011.6.JNS11129. View

5.
Nakamura M, Roser F, Michel J, Jacobs C, Samii M . The natural history of incidental meningiomas. Neurosurgery. 2003; 53(1):62-70; discussion 70-1. DOI: 10.1227/01.neu.0000068730.76856.58. View